Accelerating Immuno-Oncology Research with the PanCancer IO 360™ Gene Expression Panel, Advanced Data Analysis Service, and Signature Development

Life Sciences, Pharmaceutical, Drug Discovery & Development,
  • Thursday, December 07, 2017

Transcriptional profiling of the tumor microenvironment can lead to insights about the interaction between the tumor and immune system. This facilitates investigation of immune evasion mechanisms, enables potential development of novel therapeutics, and allows for possible identification of responder/non-responder populations in immunotherapy research.

The NanoString PanCancer IO 360™ Panel is a 770 target, multiplexed gene expression panel developed for characterization of expression patterns from the tumor, immune system, and stroma. It contains the Tumor Inflammation Signature1, which includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade.

The IO 360 panel also contains gene content to profile other mechanisms of immune evasion as well as biology relevant to tumor growth and persistence. Furthermore, NanoString has developed additional signatures that describe particular aspects of biology relevant to tumor-immune evasion, including signatures to detect 14 different immune cell populations and 15 additional biological activities such as antigen presentation, mismatch repair deficiency, cytotoxicity, interferon activity, angiogenesis, and stromal abundance.

Capturing biological activity with gene signatures can reduce complexity of data analysis and lead to improved sensitivity to detect differences between samples. The signatures being offered with the IO 360 panel are part of a new data analysis service to facilitate research and enable greater characterization of mechanisms of immune evasion.

Join this webinar to learn about how transcriptional profiling of the tumor microenvironment can lead to a better understanding of the cancer type, and support the development of more effective immunotherapies.

1Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017)


Sarah Warren, Ph.D., Director of Advanced Applications Immune Oncology, NanoString

Sarah Warren is the Director of Advanced Applications & Immune Oncology at NanoString where she leads IO collaborations and leads teams focused on new application development, IO product development, and the NanoString commercial lab. Prior to joining NanoString, she was a founder and Director of Research at Oncofactor, a startup biotech developing novel immune checkpoint therapeutics. She holds a PhD in immunology from the University of Washington and did her graduate research at the Institute for Systems Biology studying host-pathogen interactions.

Message Presenter

Patrick Danaher, Ph.D., Principal Biostatistician, NanoString

Patrick Danaher leads the biostatistics team at NanoString Technologies. Prior to joining NanoString, he earned his Ph.D. at the University of Washington Department of Biostatistics, working with Pei Wang on analysis methods for high-throughput genomics data. He began his career in gene expression at XDx, one of the first gene expression diagnostics companies.

Message Presenter

Who Should Attend?

Job Functions:

  • Research Scientists
  • Professors/Instructors
  • Core Facility Managers
  • Lab Directors/PI
  • Post Doc Students
  • Grad Students
Research Areas:

  • Biomarker discovery
  • Biomarker validation
  • Immunology
  • Pathology
  • Oncology
  • Solid Tumor
  • Translational Medicine
  • Core Facility/Service Lab

Xtalks Partner


NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company’s technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString’s products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable.

Leading researchers and institutions are finding that NanoString’s nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company’s goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account